Promote adoption of In Silico Trials through EMA’s strategy on Regulatory Science to 2025

Reasons for signing

See why other supporters are signing, why this petition is important to them, and share your reason for signing (this will mean a lot to the starter of the petition).

Thanks for adding your voice.

marco meli
2 years ago
It is of paramount importance to start using innovative methods to do trials in medical science. I fully endorse use of Silico Traials in the regulatory process

Thanks for adding your voice.

Philippe ZITOUN
2 years ago
I am afraid 60% of medicine professionals are still negative to this disruptive methodology.
Otherwise, this petition will not be here....

Thanks for adding your voice.

barry walker
2 years ago
This petition draws much needed attention to the enormous potential of in silico modelling of individual and population immune responses to disease and vaccination. Progress has been rapid and with due diligence the future for this technology and strategy to reduce clinical trials costs and human impact are profound.

Thanks for adding your voice.

Pinaki Bhattacharya
2 years ago
There is an urgent need for a systematic pipeline to efficiently bring effective medicines to the patient. In Silico Trials could potentially meet this need and the industry is well aware of this already. That is quite a good reason for the EMA to place In Silico Trials - in the fullest sense of the term - at the core of its strategy.

Thanks for adding your voice.

Ivan Fumagalli
2 years ago
As a researcher, I can say that modeling and simulation are powerful tools to provide deep insight in biological phenomena, with far less costs and risks than physical experiments and clinical trials. Thus in silico trials can help in both complementing and accelerating clinical trials in general. In addition, the development itself of in silico models can guide the research and improve knowledge about important problems.

Thanks for adding your voice.

Markus Heller
2 years ago
It is our very own experience, together with our industrial collaborators, that in silico trials can and should be an essential component in reducing cost while increasing safety during medical device development and should therefore be fully recognised as key component of a strategy for regulatory science.

Thanks for adding your voice.

Gwendolen Reilly
2 years ago
I have lots of excellent colleagues working on in silico trials which are the future of medical research

Thanks for adding your voice.

Gunther Paul
2 years ago
Clinical trials continue to be an inhibitor in medical and pharmaceutical innovation. They are costly and depend on a smaller number of trial sites. In silico has the potential to expand capacity for clinical trials and overcome cost issues. It is the most promising way to speed up clinical trials and innovation, and help those who are desperate for medical solutions.

Thanks for adding your voice.

Daniel FOUGERES
2 years ago
In silico trials is a real complement to clinical, animal and in laboratory tests to progress in innovation, cost reduction and safety in Medical Research.
FDA is going in this way and Europe should not stay behind in this opportunity who succeed in Engineering in the last decades